Oracle
ORCL
Amazon
AMZN
Alphabet-A
GOOGL
Apple
AAPL
Meta Platforms
META
US Stock MarketDetailed Quotes
LRMR Larimar Therapeutics
- 3.985
- -0.175-4.21%
Trading Dec 19 12:08 ET
254.27MMarket Cap-3.47P/E (TTM)
4.300High3.920Low621.11KVolume4.180Open4.160Pre Close2.52MTurnover1.96%Turnover RatioLossP/E (Static)63.81MShares13.68052wk High1.28P/B126.00MFloat Cap3.01052wk Low--Dividend TTM31.62MShs Float664.320Historical High--Div YieldTTM9.14%Amplitude1.530Historical Low4.060Avg Price1Lot Size
Larimar Therapeutics News
Larimar Therapeutics | 8-K: Current report
Larimar Therapeutics | 8-K: Current report
Larimar Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Blue Owl Capital Holdings LP(6.53%)
Larimar Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Janus Henderson Group plc(8.7%),Janus Henderson Biotech Innovation Master Fund Ltd(7.5%)
Larimar Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Verition Fund Management LLC(0.9%),Nicholas Maounis(0.9%)
Larimar Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-THE GOLDMAN SACHS GROUP, INC.(7.0 %),GOLDMAN SACHS & CO. LLC(7.0 %)
Larimar Therapeutics | 10-Q: Q3 2024 Earnings Report
Larimar Therapeutics | 8-K: Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results
Larimar Therapeutics | 10-Q: Q2 2024 Earnings Report
Larimar Therapeutics | 8-K: Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results
Larimar Therapeutics | 8-K: Current report
Larimar Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Flynn James E
Larimar Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Hamilton Thomas Edward
Larimar Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Truitt Joseph
Larimar Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director SHERMAN JEFFREY W
Larimar Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director LEFF JONATHAN S
Larimar Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director THOMAS FRANK E
Larimar Therapeutics | 8-K: Current report
Larimar Therapeutics | 8-K: Current report
Larimar Therapeutics | EFFECT: Others
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.